Chronic hepatitis C virus (HCV) infection remains a major global health burden, potentially leading to cirrhosis and hepatocellular carcinoma. Direct-acting antivirals (DAAs) have improved treatment outcomes, achieving high sustained virologic response (SVR) rates. However, real-world evidence from Mexico remains limited. This study aimed to evaluate DAA effectiveness in Mexican patients with chronic HCV infection and compare outcomes according to cirrhosis status. A retrospective, multicenter cohort study was conducted across five public healthcare institutions in Mexico. We included 253 patients who received DAA therapy. The primary outcome was SVR, defined as undetectable HCV RNA after treatment. Clinical, demographic, and treatment-related variables were analyzed, with statistical significance set at p < 0.05. Overall, SVR was achieved in 94.5% of patients. Among those with cirrhosis (54.1%), the SVR rate was 95.6%, compared with 93.1% among those without cirrhosis (p = 0.536). Patients with cirrhosis were older and had longer treatment durations, while baseline viral load and genotype distribution were comparable. Treatment completion was high (94.1%), with low discontinuation rates and no significant differences by cirrhosis status. DAAs were highly effective in Mexican patients with chronic HCV infection, regardless of cirrhosis status. Expanding access to diagnosis and treatment is essential to reduce disease burden and achieve hepatitis C elimination goals.

Background: Patients with type 2 diabetes mellitus (T2DM) who experience acute coronary syndromes (ACS) remain at high risk for recurrent ischemic events despite secondary prevention. Lipoprotein(a) [Lp(a)] contributes to residual cardiovascular risk, but its prognostic impact on recurrent myocardial infarction (MI) and repeat revascularization in diabetic patients after ACS or percutaneous coronary intervention (PCI) remains unclear. Hypothesis: We hypothesized that elevated Lp(a) is associated with increased risk of recurrent MI and repeat coronary revascularization in patients with diabetes after ACS or PCI. Methods: We conducted a PRISMA‐guided systematic review and meta‐analysis. PubMed, EBSCOhost, and Cochrane Library were searched for studies evaluating Lp(a) and recurrent cardiovascular outcomes in patients with diabetes after ACS or PCI. Observational studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) were included. Pooled HRs were calculated using random‐effects models. Results: Seven studies comprising 7887 patients with diabetes and prior ACS or PCI were included. Elevated Lp(a) was associated with increased risk of recurrent MI (pooled HR 2.17, 95% CI 1.02–4.62; I ² = 75%) but not repeat coronary revascularization (pooled HR 1.68, 95% CI 0.79–3.57; I ² = 78%). Conclusions: Elevated Lp(a) was associated with increased risk of recurrent MI in patients with diabetes after ACS or PCI. Findings should be interpreted considering the observational study designs, substantial heterogeneity, and limited evidence for repeat revascularization. These findings support Lp(a) as a contributor to residual cardiovascular risk and its potential role in post‐ACS risk stratification. Trial Registration: This study was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD420261296821).